Guggenheim Issues Positive Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock Price

Kymera Therapeutics (NASDAQ:KYMR) had its price target raised by Guggenheim from $45.00 to $52.00 in a research note published on Friday morning, Benzinga reports. Guggenheim currently has a buy rating on the stock.

A number of other research analysts have also recently issued reports on the company. Wolfe Research raised Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price target for the company in a report on Monday, August 26th. Oppenheimer lifted their price objective on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Friday, September 27th. B. Riley lifted their price objective on Kymera Therapeutics from $31.00 to $36.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 9th. Wells Fargo & Company lifted their price objective on Kymera Therapeutics from $30.00 to $38.00 and gave the stock an “equal weight” rating in a research report on Monday, August 12th. Finally, Truist Financial reiterated a “buy” rating and issued a $53.00 price objective (down from $54.00) on shares of Kymera Therapeutics in a research report on Friday. Four analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $49.15.

Kymera Therapeutics Trading Up 0.6 %

Shares of Kymera Therapeutics stock traded up $0.30 during trading on Friday, reaching $46.47. The company’s stock had a trading volume of 432,609 shares, compared to its average volume of 597,398. The stock has a 50-day moving average price of $47.04 and a two-hundred day moving average price of $40.65. Kymera Therapeutics has a one year low of $9.60 and a one year high of $53.27. The stock has a market capitalization of $2.87 billion, a P/E ratio of -19.20 and a beta of 2.21.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative return on equity of 28.88% and a negative net margin of 178.27%. The business had revenue of $3.74 million during the quarter, compared to analysts’ expectations of $10.34 million. During the same period in the previous year, the business posted ($0.90) earnings per share. The firm’s revenue for the quarter was down 20.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Kymera Therapeutics will post -2.85 EPS for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In other news, Director Jeffrey W. Albers sold 5,000 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $49.10, for a total transaction of $245,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Pamela Esposito sold 13,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total value of $651,780.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey W. Albers sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $49.10, for a total value of $245,500.00. The disclosure for this sale can be found here. Corporate insiders own 15.82% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of KYMR. Values First Advisors Inc. bought a new position in shares of Kymera Therapeutics during the 3rd quarter worth approximately $61,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Kymera Therapeutics by 27.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after acquiring an additional 504 shares in the last quarter. Comerica Bank grew its stake in shares of Kymera Therapeutics by 13.7% during the 1st quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after acquiring an additional 400 shares in the last quarter. Public Employees Retirement Association of Colorado bought a new position in shares of Kymera Therapeutics during the 2nd quarter worth approximately $139,000. Finally, Quest Partners LLC grew its stake in shares of Kymera Therapeutics by 1,402.0% during the 2nd quarter. Quest Partners LLC now owns 5,212 shares of the company’s stock worth $156,000 after acquiring an additional 4,865 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.